drugset / Trial / NCT01703923

An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough

NCT01703923

Phase 2 Completed 83 enrolled Avalo Therapeutics, Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to determine the antitussive effect size and dose response of FP01 lozenges in subjects with chronic cough and to demonstrate the safety and tolerability of FP01 lozenges in subjects with chronic cough.

Timeline

Start
2012-11
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 6 mg Oral
Subject Memantine Unknown 12 mg Oral

Indications

No indication recorded.